Latest H Lundbeck A/S (HLUKF) Headlines AbbVi
Post# of 4
Posted On: 03/10/2014 3:35:47 AM
Latest H Lundbeck A/S (HLUKF) Headlines
AbbVie Misses on Earnings & Revs, Focus on HCV Data - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Jan 31, 9:07AM CST
AbbVie could gain approval for its HCV combination therapy this year itself.
The Asthma Drug Market Will Remain Relatively Flat, Increasing Slightly from $15.3 Billion in 2012 to $16.2 Billion in 2022
PR Newswire - Wed Dec 18, 7:00AM CST
Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the drug market for asthma will remain relatively flat through 2022. Currently, the market is driven by maintenance therapies that successfully treat patients with mild and moderate disease, including market leaders GlaxoSmithKline's long-acting beta2 agonist (LABA)/inhaled corticosteroid (ICS) combination Advair/Seretide/Adoair and Merck's leukotriene inhibitor Singulair (montelukast). These leading agents are already beginning to face generic erosion that will lead their sales to decline.
AbbVie Misses on Earnings & Revs, Focus on HCV Data - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Jan 31, 9:07AM CST
AbbVie could gain approval for its HCV combination therapy this year itself.
The Asthma Drug Market Will Remain Relatively Flat, Increasing Slightly from $15.3 Billion in 2012 to $16.2 Billion in 2022
PR Newswire - Wed Dec 18, 7:00AM CST
Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the drug market for asthma will remain relatively flat through 2022. Currently, the market is driven by maintenance therapies that successfully treat patients with mild and moderate disease, including market leaders GlaxoSmithKline's long-acting beta2 agonist (LABA)/inhaled corticosteroid (ICS) combination Advair/Seretide/Adoair and Merck's leukotriene inhibitor Singulair (montelukast). These leading agents are already beginning to face generic erosion that will lead their sales to decline.
(0)
(0)H Lundbeck A/S (HLUKF) Stock Research Links
Scroll down for more posts ▼